ARK Innovation ETF
ARKKDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2021 | $0.78 | 2021-12-29 | 2021-12-30 |
| December 31, 2020 | $2.04 | 2020-12-29 | 2020-12-30 |
| December 31, 2019 | $0.19 | 2019-12-27 | 2019-12-30 |
| December 31, 2018 | $1.09 | 2018-12-27 | 2018-12-28 |
| December 31, 2018 | $0.08 | 2018-12-27 | 2018-12-28 |
Dividends Summary
- Consistent Payer: ARK Innovation ETF has rewarded shareholders with 9 dividend payments over the past 6 years.
- Total Returned Value: Investors who held ARKK shares during this period received a total of $5.14 per share in dividend income.
- Latest Payout: The most recent dividend of $0.78/share was paid 1484 days ago, on December 31, 2021.
- Yield & Schedule: ARKK currently pays dividends yearly with an annual yield of 0.95%.
- Dividend Growth: Since 2015, the dividend payout has grown by 68.3%, from $0.47 to $0.78.
Company News
PayPal announced the acquisition of Cymbio, an Israel-based multi-channel orchestration platform, to strengthen its agentic commerce capabilities. The deal, expected to close in H1 2026, will enable merchants to place product catalogs in AI shopping environments like Microsoft Copilot and Perplexity. Cymbio has powered PayPal's Store Sync service...
Ark Invest unveiled its 'big ideas' for 2026 through cryptic ARKmoji images, challenging users to interpret six investment themes: AI Agents, Genomics, Space Race (reusable rockets), Cryptocurrencies/Tokenization, Robotics, and The Great Acceleration. The firm highlighted portfolio holdings aligned with each theme, spanning multiple sectors from ...
The article recommends four growth ETFs for investors with $1,000 to invest. The Vanguard Growth ETF (VUG) and Invesco QQQ Trust (QQQ) are highlighted as strong index-based options with consistent outperformance. The Global X Artificial Intelligence & Technology ETF (AIQ) offers AI-focused exposure with international diversification. The Ark Inno...
The ARK Innovation ETF has underperformed compared to other tech ETFs, losing 28% over five years, while the Vanguard Information Technology ETF has gained 124% during the same period due to better diversification and strategic holdings.
Cathie Wood continues investing in CRISPR Therapeutics, a gene editing biotech company with its first approved treatment Casgevy. Despite a stock price decline, Wall Street analysts predict a potential 50% increase due to promising technology and emerging revenue streams.
